Home
Home

Xtandi

Astellas forecasts big sales growth as prostate drug catches hold

Astellas forecasts big sales growth as prostate drug catches hold
Fierce Pharma

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL
Yahoo/Fly on the Wall

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players
Motley Fool

Medivation falls after analyst says Xtandi must overcome obstacles

Medivation falls after analyst says Xtandi must overcome obstacles
The Fly on the Wall

Johnson & Johnson's Pioneering Zytiga And Its Competitors

Johnson & Johnson's Pioneering Zytiga And Its Competitors
Seeking Alpha

Court rules against Medivation in fight with UCLA over cancer drug

Court rules against Medivation in fight with UCLA over cancer drug
Yahoo/Fly on the Wall

10 Drugs Approved by the FDA in 2012 to Be Thankful For

10 Drugs Approved by the FDA in 2012 to Be Thankful For
Motley Fool

After XTANDI's FDA Approval, Medivation Pulls Back

After XTANDI's FDA Approval, Medivation Pulls Back
Seeking Alpha

Zytiga, Xtandi will help pump prostate cancer market to $9.1B

Zytiga, Xtandi will help pump prostate cancer market to $9.1B
Fierce Pharma

Medivation Prostate Cancer Drug Launches Hot

Medivation Prostate Cancer Drug Launches Hot
TheStreet.com